UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Interleukin-6 as a therapeutic target

Clinical cancer research, 2015-03, Vol.21 (6), p.1248-1257

2015

Volltextzugriff (PDF)

GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells

PLoS computational biology, 2015-01, Vol.11 (1), p.e1004077-e1004077

2015

Volltextzugriff (PDF)

Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138− and CD138+ plasma cells

Haematologica (Roma), 2010-06, Vol.95 (6), p.1016-1020

2010

Volltextzugriff (PDF)

SULFs in human neoplasia: implication as progression and prognosis factors

Journal of translational medicine, 2011-05, Vol.9 (1), p.72-72, Article 72

2011

Volltextzugriff (PDF)

A gene expression signature shared by human mature oocytes and embryonic stem cells

BMC genomics, 2009-01, Vol.10 (1), p.10-10, Article 10

2009

Volltextzugriff (PDF)

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

Haematologica (Roma), 2011-04, Vol.96 (4), p.574-582

2011

Volltextzugriff (PDF)

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

Blood, 2004-04, Vol.103 (8), p.3148-3157

2004

Volltextzugriff (PDF)

Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation

The Journal of immunology (1950), 2011-10, Vol.187 (8), p.3931-3941

2011

Volltextzugriff (PDF)

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

Haematologica (Roma), 2011-01, Vol.96 (1), p.87-95

2011

Volltextzugriff (PDF)

Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma

Cancer research (Chicago, Ill.), 2012-03, Vol.72 (6), p.1395-1406

2012

Volltextzugriff (PDF)

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells

British journal of cancer, 2018-04, Vol.118 (8), p.1062-1073

2018

Volltextzugriff (PDF)

Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling

Frontiers in immunology, 2022-07, Vol.13, p.919489-919489

2022

Volltextzugriff (PDF)

γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody

Haematologica (Roma), 2011-03, Vol.96 (3), p.400-407

2011

Volltextzugriff (PDF)

Characterization of human FCRL4-positive B cells

PloS one, 2017-06, Vol.12 (6), p.e0179793-e0179793

2017

Volltextzugriff (PDF)

Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors

Molecular cancer therapeutics, 2012-12, Vol.11 (12), p.2685-2692

2012

Volltextzugriff (PDF)

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

Blood, 2009-05, Vol.113 (19), p.4614-4626

2009

Volltextzugriff (PDF)

Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration

Blood, 2011-01, Vol.117 (4), p.1280-1290

2011

Volltextzugriff (PDF)

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells

Cancers, 2019-03, Vol.11 (4), p.439

2019

Volltextzugriff (PDF)

Survival and proliferation factors of normal and malignant plasma cells

International journal of hematology, 2003-08, Vol.78 (2), p.106-113

2003

Volltextzugriff (PDF)

Induction of angiogenesis by normal and malignant plasma cells

Blood, 2009-07, Vol.114 (1), p.128-143

2009

Volltextzugriff (PDF)

CD200: A putative therapeutic target in cancer

Biochemical and biophysical research communications, 2008-02, Vol.366 (1), p.117-122

2008

Volltextzugriff (PDF)

Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells

PloS one, 2013-04, Vol.8 (4), p.e62752-e62752

2013

Volltextzugriff (PDF)

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma

Blood, 2007-06, Vol.109 (11), p.4914-4923

2007

Volltextzugriff (PDF)

APRIL is overexpressed in cancer: link with tumor progression

BMC cancer, 2009-03, Vol.9 (1), p.83-83, Article 83

2009

Volltextzugriff (PDF)

1 – 25 von 1.227

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(982)
Mit Volltextzugriff
(1.008)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.152)
Japanisch
(136)
Französisch
(53)
Deutsch
(27)
Italienisch
(1)
Spanisch
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(115)
Clinical Chemistry
(47)
British Journal Of Haematology
(25)
Plos One
(17)
The Journal Of Immunology
(17)
Recherches & Éducations
(13)
The New England Journal Of Medicine
(13)
Haematologica
(12)
The journal Of Immunology/the journal Of Immunology
(12)
Oncogene
(11)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Interleukin-6 as a therapeutic target

GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells

Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138− and CD138+ plasma cells

SULFs in human neoplasia: implication as progression and prognosis factors

A gene expression signature shared by human mature oocytes and embryonic stem cells

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial

Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells

Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling

γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody

Characterization of human FCRL4-positive B cells

Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells

Survival and proliferation factors of normal and malignant plasma cells

Induction of angiogenesis by normal and malignant plasma cells

CD200: A putative therapeutic target in cancer

Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma

APRIL is overexpressed in cancer: link with tumor progression

Suchergebnisse filtern